---
schema_version: "secwatch.filing_event.v1"
accession: "0001711279-24-000023"
form_type: "8-K"
ticker: "KRYS"
cik: "0001711279"
company_name: "Krystal Biotech, Inc."
filed_at: "2024-05-08T23:59:59+00:00"
generated_at: "2026-06-02T11:41:14.759369+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "medium"
source: SEC EDGAR
---

# Krystal Biotech presents preclinical ocular gene therapy data at ARVO 2024

## Summary
- Subretinal and suprachoroidal injections achieved widespread mCherry expression across the retina in mice.
- Vector transduced both photoreceptors (RHO+) and RPE cells (RPE65+) with minimal inflammation.
- Intravitreal injection resulted in mCherry signal in cornea, iris, and ciliary body, not retina.
- Low systemic dissemination detected; platform shows potential for inherited retinal diseases (IRDs).

## SEC filing metadata
- accession: 0001711279-24-000023
- form_type: 8-K
- ticker: KRYS
- cik: 0001711279
- company_name: Krystal Biotech, Inc.
- filed_at: 2024-05-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: medium
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711279/000171127924000023/0001711279-24-000023-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711279/000171127924000023/krys-20240507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001711279-24-000023
- JSON: https://secwatch.observer/filing/0001711279-24-000023.json
- Plain text: https://secwatch.observer/filing/0001711279-24-000023.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.